Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8%

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 867,767 shares, an increase of 60.8% from the December 31st total of 539,567 shares. Approximately 18.6% of the company's stock are sold short. Based on an average trading volume of 100,271 shares, the days-to-cover ratio is presently 8.7 days. Based on an average trading volume of 100,271 shares, the days-to-cover ratio is presently 8.7 days. Approximately 18.6% of the company's stock are sold short.Get Kalaris Therapeutics alerts:Hedge Funds Weigh In On Kalaris TherapeuticsLarge investors have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. bought a new stake in Kalaris Therapeutics during the third quarter valued at $58,000. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the 2nd quarter worth about $65,000. Bridgeway Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the 3rd quarter valued at about $130,000. Belpointe Asset Management LLC bought a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at about $231,000. Finally, Fortis Capital Advisors LLC bought a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at about $231,000. 66.05% of the stock is currently owned by institutional investors. Analysts Set New Price TargetsA number of analysts have recently issued reports on KLRS shares. Citizens Jmp started coverage on shares of Kalaris Therapeutics in a research note on Monday, November 3rd. They set a "market outperform" rating and a $20.00 price objective on the stock. Citigroup reaffirmed an "outperform" rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Chardan Capital started coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a "buy" rating and a $19.00 price objective on the stock. Wall Street Zen cut shares of Kalaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $14.00.View Our Latest Stock Report on KLRSKalaris Therapeutics Stock PerformanceShares of Kalaris Therapeutics stock traded down $0.32 during trading on Friday, reaching $8.88. The company had a trading volume of 43,068 shares, compared to its average volume of 74,560. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $12.90. The firm's fifty day moving average is $8.42 and its 200-day moving average is $5.72. The company has a market cap of $166.06 million, a price-to-earnings ratio of -2.36 and a beta of -0.09. Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02. Kalaris Therapeutics Company Profile (Get Free Report)Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.Read MoreFive stocks we like better than Kalaris TherapeuticsDo not delete, read immediatelyNEW LAW: Congress Approves Setup For Digital Dollar?“Fed Proof” Your Bank Account with THESE 4 Simple StepsA U.S. “birthright” claim worth trillions - activated quietlyThe Crash Has Already Started (Most Just Don’t See It Yet)This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Kalaris Therapeutics Right Now?Before you consider Kalaris Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kalaris Therapeutics wasn't on the list.While Kalaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here